I have read the rule's summary, dates and contact list in the version supplied to me. That text is partial. It cuts off in the middle of the Part D drug rebate section, so the dollar figures, payment rates and conversion factor that most physicians will look for sit in addenda the rule points to on the CMS website. I have not included any of them here because they are not in the text I worked from.
Who it affects
The rule covers a wide set of Medicare programs. The Federal Register summary lists changes to the physician fee schedule, drugs and biologicals paid under Part B, the Medicare Shared Savings Program, the Quality Payment Program, Rural Health Clinics and Federally Qualified Health Centers, the Ambulance Fee Schedule, the Clinical Laboratory Fee Schedule, and the Medicare Promoting Interoperability Program.
It also codifies several policies that apply to the Medicare Prescription Drug Inflation Rebate Program, the Ambulatory Specialty Model, and a rule limiting Medicare coverage of certain individuals. Each of those has its own agency contact in the document.
If you are a Medicare beneficiary who does not bill Part B or take a Part B drug, the document's main effects reach you mostly through what your physician charges and what the program covers. The summary does not spell out beneficiary cost-sharing changes beyond the Shared Savings Program item on reducing or eliminating Part B cost sharing for ACO patients.
If you are a clinician in a Rural Health Clinic or FQHC, or you bill for ambulance services or lab tests, the sections on those programs apply to you directly.
What the rule does, by topic
The rule modifies payment for drugs and biologicals under Part B, and it clarifies several inflation rebate items. For the Part B rebate program, it explains how the Consumer Price Index for all Urban Consumers is identified when survey data for the payment amount benchmark quarter are missing, and how the rebate is calculated in those cases. It clarifies the definition of "first marketed date. It also states that certain skin substitutes would not be excluded from the definition of a Part B rebatable drug. That last point matters for anyone who buys or bills skin substitutes, because it means those products stay inside the rebate calculation.
For the Part D rebate program, the rule sets the same kind of CPI-U fallback for the payment amount benchmark period and the applicable period. It also changes the methodology the agency set in the CY 2026 PFS final rule. The change accounts for 340B-eligible units for AIDS Drug Assistance Program clients for the applicable period beginning October 1, 2025. The document says Medicare providers and suppliers that are 340B covered entities must submit Part D 340B claims data to the Medicare Part D Claims Data 340B Repository. The text I have cuts off just as it starts to give the start date for that submission requirement, so I will not guess at it.
The rule also lists a set of statutes it implements, including the Inflation Reduction Act of 2022 and the Consolidated Appropriations Act, 2026 (Pub. L. 119-75, February 3, 2026). Several provisions from those laws are now written into the regulations.
What to do, in order
The document itself does not give a checklist for practices or beneficiaries. The steps below follow from the contact list and the stated effective date.
First, note the January 1, 2027 effective date. Nothing in this rule changes payment for services billed before that day.
Second, pull the addenda. The text says the Physician Fee Schedule addenda and supporting tables are posted on the CMS Physician Fee Schedule page at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/index.html. Look for the item labeled "PFS Federal Regulations Notices" and the CY 2027 final rule item, CMS-1848-F. Those tables hold the numbers this article cannot give you.
Third, find the contact for your issue. The document lists a named CMS contact for each topic. For example, Amy Gruber at (410) 786-1542 handles the Ambulance Fee Schedule. Patrick Sartini at (410) 786-9252 handles the Clinical Laboratory Fee Schedule. Kati Moore at (410) 786-5471 handles MIPS questions. For questions about reporting a service on a claim, the document says to contact your Medicare Administrative Contractor, not CMS.
Fourth, if you use the Shared Savings Program, check the contact for your question. Lucy Bertocci, at (443) 681-0762, is listed for reducing or eliminating Part B cost sharing, prepaid shared savings, beneficiary notifications, and advance investment payments.
What we don't know yet
The text I have does not state the 2027 conversion factor, the fee schedule payment amounts, or the Part B and Part D rebate figures. It does not give a start date for the 340B claims submission requirement. It does not say how the "limiting Medicare coverage of certain individuals" provision works or who it reaches, because the summary names the topic and sends readers to Steve Manning at (410) 786-1691. I could not find the specifics in what I was given, so I will not describe them.
The rule also adopts many changes the summary groups under one sentence each. Some may matter a great deal to a single specialty. Until someone checks the full preamble and addenda, I would treat any specialty-specific effect as unconfirmed.
General information, not legal, immigration or tax advice. Confirm the details with Health and Human Services Department before you act.
